GlassScriptPhysician profile
David John Szafron
NPI 1992232375
$3,057.20
in general payments reported to CMS, 2019-2025
20 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.09 · 2022: $783 · 2023: $913 · 2024: $673 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.39 | 2022-2025 | Mavyret, Linzess, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $368.71 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Conmed Corporation | $341.77 | 2022-2025 | Conmed Generators, Conmed Dilation, Conmed Hemostasis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.13 | 2022-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $212.23 | 2021-2025 | Stelara, Tremfya |
| Apollo Endosurgery US INC | $196.09 | 2021-2022 | |
| Enterra Medical, INC. | $152.43 | 2025 | |
| Medtronic, INC. | $147.48 | 2025 | Endoflip |
| Merck Sharp & Dohme LLC | $147.05 | 2023-2024 | Dificid |
| Genzyme Corporation | $110.29 | 2022-2025 | |
| Boston Scientific Corporation | $96.03 | 2021-2023 | Orise |
| Celgene Corporation | $53.17 | 2023 | Zeposia |
| Qol Medical, LLC | $46.14 | 2022-2023 | Sucraid |
| Alcresta Therapeutics, INC. | $46.07 | 2022-2023 | Relizorb |
| Intercept Pharmaceuticals, INC. | $44.29 | 2022-2024 | Ocaliva |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.81 | 2023 | |
| Gilead Sciences, INC. | $22.83 | 2024 | Epclusa |
| Aimmune Therapeutics, INC. | $22.79 | 2025 | Zenpep |
| Novo Nordisk INC | $18.44 | 2025 | Wegovy |
| Laborie Medical Technologies Corp. | $15.06 | 2024 | Alphaone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Szafron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.